下肢深静脉血栓形成的溶栓治疗现状与尿激酶、阿替普酶的临床应用

doi:10.3877/cma.j.issn.2095-5782.2017.04.016

下肢深静脉血栓形成是临床常见静脉回流障碍性血管疾病之一。在抗凝治疗基础上，溶栓治疗不失为一种积极有效的策略选择，深受国内外学者的关注。因此，探寻一个既能高效清除血栓又可减少出血的最佳纤溶药物、剂量和溶栓模式有着重要意义。目前，尿激酶和阿替普酶是国内外下肢深静脉血栓形成溶栓中最常应用的溶栓剂，对于溶栓药物的给药剂量及模式在不同研究机构中多为经验性应用。本文就目前下肢溶栓治疗中尿激酶和阿替普酶的溶栓速率、剂量、有效性及安全性的临床应用现状作一综述。

关键词: 尿激酶, 阿替普酶, 深静脉血栓形成, 溶栓, 介入性

Deep venous thrombosis (DVT) is one of the most common venous reflux disorders in vascular disease. On the basis of anticoagulant therapy, thrombolytic therapy is an active and effective option that has drawn a wide attention of international researchers and clinicians in the field. Therefore, it is of great significance to explore the best thrombolytic drug, dosage and thrombolytic mode, which not only can effectively remove thrombus but also can reduce bleeding. At present, urokinase and rt-PA are the most prevalent thrombolytic agents in the treatment of DVT worldwide, and most of the studies on the dosage and mode of such thrombolytic drugs conducted by various research groups and labs stay at empirical level. In this article, we make a comprehensive review concerning the current situation of thrombolysis rate, dosage, efficacy and safety of urokinase and rt-PA in clinical application for DVT on thrombolysis.

Key words: Urokinase, rt-PA, deep Venous thrombosis, Thrombolysis, Interventional

1	中华医学会放射学分会介入学组.下肢深静脉血栓形成介入治疗规范的专家共识[J].中华放射学杂志,2011, 45(3):293-296. doi:10.3760/cma.j.issn.1005-1201.2011.03.014.
2	Rodriguez AL, Wojcik BM, Wrobleski SK，et al. Statins，inflammation and deep vein thrombosis: a systematic review[J]. J Thromb Thrombolysis,2012, 33(4):371-82. doi: 10.1007/s11239-012-0687-9.
3	Chen G, Shi W, He X, et al. Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding[J]. Exp Ther Med,2017, 13(2):751-758. doi:10.3892/etm.2017.4023.
4	Righini M, Le Gal G, Bounameaux H. Venous thromboembolism diagnosis: unresolved issues[J]. Thromb Haemost，2015，113(6):1184-1192. doi: 10.1160/TH14-06-0530.
5	Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report[J]. Chest，2016，149(2):315-152. doi: 10.1016/j.chest.2015.11.026.
6	Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis[J]. Ann Intern Med,2008, 149(10):698-707.
7	Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism[J]. J Thromb Thrombolysis,2016, 41(1):32-67. doi: 10.1007/s11239-015-1317-0.
8	Haig Y, Enden T, Slagsvold CE, et al. Determinants of early and longterm efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis[J]. J Vasc Interv Radiol,2013, 24(1):17-24; quiz 26. doi:10.1016/j.jvir.2012.09.023.
9	Enden T, Haig Y, Klow NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis(the CaVenT study): a randomised controlled trial[J]. Lancet, 2012, 379(9810): 31-38. doi: 10.1016/S0140-6736(11)61753-4.
10	Haig Y, Enden T, Grptta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis(CaVenT):5-year follow-up results of an open-label, randomised controlled trial[J]. Lancet Haematol, 2016, 3(2): e64-71. doi: 10.1016/S2352-3026(15)00248-3.
11	Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis[J].Cochrane Database Syst Rev, 2016, 11:CD002783.
12	Du XL, Kong LS, Meng QY, et al. Safety and efficacy of low dosage of urokinase for catheter-directed thrombolysis of deep venous thrombosis[J]. Chin Med J (Engl), 2015, 128(13): 1787-1792. doi: 10.4103/0366-6999.159355.
13	Kahn SR, Partsch H, Vedantham S，et al. Definition of postthrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization[J]. J Thromb Haemost, 2009, 7(5):879-883. doi: 10.1111/j.1538-7836.2009.03294.x.
14	Engelberger RP, Spirk D, Willenberg T, et al. Ultrasoundassisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis[J]. Circ Cardiovasc Interv, 2015, 8(1). pii: e002027. doi: 10.1161/CIRCINTERVENTIONS.114.002027.
15	Gacia MJ, Lookstein R, Malhotra R, et al. Endovascular management of deep vein thrombosis with rheolytic thrombectomy: final report of the prospective multicenter PEARL(Peripheral Use of AngioJet Rheoiytic Thrombectomy with a variety of Catheter Lengths) Registry[J]. J Vasc Interv Radiol, 2015, 26(6): 777-785; quiz 786. doi: 10.1016/j.jvir.2015.01.036.
16	宋进华，何旭，楼文胜,等.急性髂股静脉血栓治疗中AngioJet机械性血栓清除装置初步应用结果[J].中华放射学杂志, 2015, 49(10):758-762.doi:10.3760/cma.j.issn.1005-1201.2015.10.009.
17	Du GC, Zhang MC, Zhao JC. Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis a meta analysis[J]. Vasa, 2015, 44(3):195-202. doi: 10.1024/0301-1526/a000430.
18	Vedantham S, Sista AK, Klein SJ, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal[J]. J Vasc Interv Radiol, 2014, 25(9):1317-1325. doi: 10.1016/j.jvir.2014.04.019.
19	陈国平，顾建平，何旭,等.顺行与逆行插管途径介入治疗急性下肢深静脉血栓形成的疗效比较[J].中华医学杂志, 2017, 97(5):353-358.doi:10.3760/cma.j.issn.0376-2491.2017.05.007.
20	刘辉，承文龙，卢辉俊.导管溶栓与系统溶栓治疗急性下肢深静脉血栓形成的Meta分析[J].中国血管外科杂志:电子版, 2016, 8(3):183-187.doi:10.3969/j.issn.1674-7429.2016.03.005.
21	Vedantham S, Piazza G, Sista AK, et al. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism [J]. J Thromb thrombolysis，2016，41(1):68-80. doi：10.1007/s11239-015-1318-z.
22	Jeon YS, Yoon YH, Cho JY, et al. Catheter-directed thrombolysis with conventional aspiration thrombectomy for lower extremity deep vein thrombosis[J].Yonsei Med J, 2010, 51(2):197-201. doi: 10.3349/ymj.2010.51.2.197.
23	Fiengo L, Bucci F, Khalil E, et al. Original approach for thrombolytic therapy in patients with Ilio-femoral deep vein thrombosis: 2 years follow-up[J]. Thromb J, 2015,13:40. doi: 10.1186/s12959-015-0070-0.
24	Khan JU, Takemoto CM, Casella JF, et al. Catheter-directed thrombolysis of inferior vena cava thrombosis in a 13-day-old neonate and review of literature[J]. Cardiovasc Intervent Radiol, 2008, 31(Suppl 2):S153-160.
25	Kukreja KU, Lungren MP, Patel MN, et al. Endovascular venous thrombolysis in children younger than 24 months[J]. J Vasc Interv Radiol, 2014, 25(8):1158-1164. doi: 10.1016/j.jvir.2014.04.003.
26	Grünewald M, Griesshammer M, Ellbrück D, et al. Loco-regional thrombolysis for deep vein thrombosis: fact or fiction A study of hemostatic parameters[J]. Blood Coagul Fibrinolysis, 2000, 11(6):529-536.
27	Sharifi M, Bay C, Nowroozi S, et al. Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2013, 36(6):1586--590. doi: 10.1007/s00270-013-0569-3.
28	Lungren MP, Ward TJ, Patel MN, et al. Endovascular thrombolysis to salvage central venous access in children with catheter-associated upper extremity deep vein thrombosis: technique and initial results[J]. J Thromb Thrombolysis, 2015, 40(3):274-279. doi: 10.1007/s11239-015-1209-3.
29	Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry[J].Radiology, 1999, 211(1):39-49.
30	Xue GH, Huang XZ, Ye M, et al. Catheter-directed thrombolysis and stenting in the treatment of iliac vein compression syndrome with acute iliofemoral deep vein thrombosis: outcome and follow-up[J]. Ann Vasc Surg, 2014, 28(4):957-963. doi: 10.1016/j.avsg.2013.11.012.
31	Manninen H, Juutilainen A, Kaukanen E, et al. Catheter-directed thrombolysis of proximal lower extremity deep vein thrombosis: a prospective trial with venographic and clinical follow-up[J]. Eur J Radiol, 2012, 81(6):1197-1202. doi: 10.1016/j.ejrad.2011.03.068.
32	Lee K, Istl A, Dubois L, et al. Fibrinogen level and bleeding risk during catheter-directed thrombolysis using tissue plasminogen activator[J]. Vasc Endovascular Surg, 2015, 49(7): 175-179. doi: 10.1177/1538574415611234.
33	Chang R, Horne MK 3rd, Shawker TH, et al. Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis[J]. J Vasc Interv Radiol, 2011, 22(8): 1107-1116. doi: 10.1016/j.jvir.2011.03.023.
34	Gurman P, Miranda O, Nathan A, et al. Recombinant tissue plasminogen activators(rtPA): a review[J]. Clin Pharmacol Ther, 2015, 97(3):274-285. doi: 10.1002/cpt.33.
35	Sugimoto K, Hofmann LV, Razavi MK, et al. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions[J]. J Vasc Surg, 2003, 37(3):512-517.
36	Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis[J]. J Vasc Interv Radio, 2004, 15(4):347-352.
37	Howard LS, Hughes RJ. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing[J]. Thorax, 2013, 68(4):391-393. doi: 10.1136/thoraxjnl-2012-202376.
38	Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog[J]. Thromb Haemost, 1994,72(1):98-104.
39	Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl): 887S-968S. doi: 10.1378/chest.08-0762.
40	中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南(第2版)[J].中华外科杂志, 2012, 50(7):611-614.doi: 10.3760/cma.j.issn.0529-5815.2012.07.010.
41	Jaff MR, Mcmurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension a scientific statement from the American Heart Association[J]. Circulation，2011，123(16):1788-830. doi: 10.1161/CIR.0b013e318214914f.

[1]	罗辉, 方晔. 品管圈在提高甲状腺结节细针穿刺检出率中的应用[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(10): 972-977.
[2]	赵里汶, 贺需旗, 李凯. 虚拟导航辅助超声引导下经皮射频消融治疗直径≤2 cm肾上腺良性肿瘤的疗效研究[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(12): 1282-1286.
[3]	廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
[4]	唐全兴, 周畅. 维持性血液透析患者血清suPAR对动静脉内瘘狭窄发生的诊断价值[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 74-78.
[5]	周帅, 张庆海, 王新, 马晓艳, 孙建霞, 王海波, 张继红. 静脉-动脉体外膜肺氧合辅助下溶栓治疗急性高危肺栓塞一例[J/OL]. 中华重症医学电子杂志, 2024, 10(03): 298-302.
[6]	倪管崟, 缪小赟, 丁家安, 田鹏程, 倪才方. 锥形束计算机断层扫描在肝癌介入诊疗中的应用进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(03): 256-260.
[7]	刘一人, 崔世军, 佟铸, 郭建明, 杨盛家, 谷涌泉, 郭连瑞. 急性肠系膜上动脉栓塞的介入治疗[J/OL]. 中华介入放射学电子杂志, 2024, 12(02): 131-136.
[8]	王勇, 王丽. 导管接触性溶栓治疗下肢深静脉血栓安全性和有效性的系统评价再评价[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 58-63.
[9]	葛静萍, 尹媛媛, 李燕. 梯度压力袜联合间歇充气加压在老年新型冠状病毒肺炎患者预防下肢深静脉血栓形成中的应用[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 70-74.
[10]	胡浩, 曹葳, 何益兴, 安天志. 导管接触性溶栓治疗卵巢静脉血栓二例并文献复习[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 90-92.
[11]	王海珍, 马永明, 姚可盈. 尿激酶治疗结核性包裹性胸腔积液疗效的系统评价与荟萃分析[J/OL]. 中华胸部外科电子杂志, 2024, 11(01): 53-61.
[12]	潘鑫, 黄晓云, 王超, 顾慧, 唐加波, 王鹏, 崔恒熙, 李政. 院前亚低温结合院内溶栓救治急性脑梗死的效果[J/OL]. 中华卫生应急电子杂志, 2024, 10(03): 145-148.
[13]	穆巴拉克·伊力哈, 徐霁华, 鲁明. 急性轻型卒中微量脑出血误诊病例的临床特点及影像学表现分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 441-445.
[14]	李芳, 戴西望, 王凯, 郭廷昊, 涂江龙. 非瓣膜性心房颤动相关性卒中的治疗研究进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(04): 393-397.
[15]	张华纲, 王小倩, 张晨, 傅瑜, 李小刚, 樊东升, 王悦, 石菊, 毕书红. 急性脑梗死患者住院费用的趋势及其影响因素的研究——基于北京市某三甲医院的分析[J/OL]. 中华脑血管病杂志(电子版), 2023, 17(06): 557-564.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Review of thrombolytic therapy for deep venous thrombosis and clinical application of urokinase and rt-PA

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Review of thrombolytic therapy for deep venous thrombosis and clinical application of urokinase and rt-PA